|
Hedging Transactions and Derivative Financial Instruments (Details) (Gain (Loss) from Hedging Transactions) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 28, 2013
|
Sep. 28, 2013
|
Jun. 29, 2013
|
Mar. 30, 2013
|
Dec. 29, 2012
|
Sep. 29, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 28, 2013
|
Dec. 29, 2012
|
Dec. 31, 2011
|
|
| Foreign Currency Forward Contracts [Line Items] | |||||||||||
| Research and development | $ (293) | $ (288) | $ (308) | $ (312) | $ (313) | $ (328) | $ (345) | $ (368) | $ (1,201) | $ (1,354) | $ (1,453) |
| Marketing, general and administrative | (169) | (155) | (171) | (179) | (193) | (188) | (212) | (230) | (674) | (823) | (992) |
| Other income (expense), net | (2) | 2 | (2) | (3) | (4) | 16 | (5) | (1) | (5) | 6 | (199) |
|
Contracts Designated as Cash Flow Hedging Instruments
|
|||||||||||
| Foreign Currency Forward Contracts [Line Items] | |||||||||||
| Other comprehensive income (loss) | (3) | 2 | |||||||||
| Research and development | (2) | 0 | |||||||||
| Marketing, general and administrative | (1) | 0 | |||||||||
|
Contracts not Designated as Hedging Instruments
|
|||||||||||
| Foreign Currency Forward Contracts [Line Items] | |||||||||||
| Other income (expense), net | $ (2) | $ 1 | |||||||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|